When doctors look for ways to predict how a cancer will behave, they often look for specific markers in the body. A recent review of data shows that a protein called NLRP-3 is a significant marker for patients with solid cancers, including head and neck, colorectal, and pancreatic cancers.
Patients with higher levels of this protein faced much worse outcomes. Specifically, those with high NLRP-3 expression had shorter overall survival times and were more likely to have disease that returned quickly. The data showed these risks were particularly high in pancreatic cancer patients, where the link to poor survival was very strong.
Beyond just survival time, higher NLRP-3 levels were also linked to physical signs of advanced disease. This included larger tumors, higher tumor grades, and more instances of metastasis, which is when cancer spreads to other parts of the body. While this study shows a clear link between the protein and worse outcomes, it is an analysis of existing data rather than a test of a new treatment.
